Amgen Inc. (NASDAQ: AMGN) earnings surpassed analysts’ expectations

Amgen Inc. profits grow

In brief: Amgen Inc. (NASDAQ: AMGN) receives a profit on the background of an overall positive mood of investors.

U.S. biotechnology company Amgen Inc. (NASDAQ: AMGN) has published data on the profit for the second quarter of 2010, surpassed expectations of analysts. It Amgen said that the launch of a new drug for the treatment of osteoporosis Prolia passes under the planned scheme.

It is reported that adjusted earnings excluding certain items was $ 1.38 per share, surpassing analysts’ expectations by 8 cents. ” Net income fell to $ 1.20 billion, or $ 1.25 per share, compared with $ 1.27 billion, or $ 1.25 per share, a year earlier. Revenues in the second quarter totaled $ 3.8 billion, analysts had expected $ 3.74. It is worth noting that Amgen Inc. adjusted the forecast for annual sales to a little less than $ 15.1 billion because of the weakening euro. It forecast adjusted earnings in 2010 remained unchanged at $ 5.05 – $ 5.25 per share.

Anrey Torbinski
2010-07-30 18:38, Economics.

News on: , , , , , , ,

Post a comment

E-